Zika Virus Therapeutics Market Worth USD 33.21 Million, at 4% CAGR During 2019-2023 | Technavio
June 19, 2019LONDON–(BUSINESS WIRE)–#Biotechnology–According to Technavio Research Report “Zika Virus
Therapeutics Market by product (acetaminophen, and other NSAIDs) and
geographic regions (ROW, North America, Asia, and Europe) is
witnessed to grow USD 33.21 million, at a CAGR of 4% from 2019 to 2023”.
Free sample report contains market size and forecast, drivers,
challenges, trends, and more – Request for Sample @ https://www.technavio.com/talk-to-us?report=Global+Zika+Virus+Therapeutics+Market+2019-2023&type=sample&src=report
Global Zika Virus Therapeutics Market: Novel
approach for vaccine development
Various novel approaches are being developed to treat the chronic health
conditions occurring due to the Zika virus. Vendors in the market are
developing vaccines with modified RNA activity. These vaccines consist
of a lipid capsule encapsulating nanoparticle which is administered
through the intramuscular route. They also contain a modified messenger
RNA (mRNA), which is non-self-amplifying and optimizes the intracellular
stability, translation, and proprietary nucleoside alteration to prevent
the stimulation of innate immune response. Another vaccine developed
contains modified nucleoside 1-methylpseudouridine, which increases the
translation of mRNA. These newly developed vaccines are targeted at
producing a high concentration of antibodies against Zika virus
infection. Thus, the development of RNA vaccines against Zika virus is
likely to pave the way for other researchers to facilitate further R&D
in this area.
“Various government and non-government bodies are taking various
initiatives to develop vaccines against the Zika virus. Also, private
organizations are developing purified, inactivated, and whole virus
vaccines against the Zika virus infection. These initiatives and efforts
are further likely to contribute to the market’s growth during the
forecast period,” says a senior research analyst at Technavio.
Speak to Research Expert @ https://www.technavio.com/talk-to-us?report=Global+Zika+Virus+Therapeutics+Market+2019-2023&type=customization
Global Zika Virus Therapeutics Market:
Segmentation analysis
This market research report segments the global Zika virus therapeutics
market by product (acetaminophen, and other NSAIDs) and geographic
regions (ROW, North America, Asia, and Europe).
ROW led the market in 2018, followed by North America, Asia, and Europe
respectively. The region is expected to grow faster than the overall
market owing to increasing instances of this medical condition.
Global Zika Virus Therapeutics Market: Rising
prevalence of and burden of Zika virus
Zika virus infection gradually has witnessed several outbreaks reported
from various parts of the world. It is transmitted by infected mosquitos
and results in non-specific symptoms, including fever, myalgia, and
generalized fatigue. The market is witnessing a high incidence of the
Zika virus, which is expected to increase the patient pool leading to
increased consumption of Zika virus therapeutics. Thus, the growing
prevalence and burden of Zika virus infection and associated
comorbidities will foster market growth during the forecast period.
Few Major Players for the Zika Virus Therapeutics Market are:
- Aurobindo Pharma Ltd.
- Johnson & Johnson Services Inc.
- Perrigo Co. Plc
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
Browse Industries Reports @ Pharmaceuticals,
Biotechnology & Life Sciences
About Technavio
Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at [email protected].
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com
Zika Virus Therapeutics Market Worth USD 33.21 Million, at 4% CAGR During 2019-2023 | Technavio
June 19, 2019LONDON–(BUSINESS WIRE)–#Biotechnology–According to Technavio Research Report “Zika Virus
Therapeutics Market by product (acetaminophen, and other NSAIDs) and
geographic regions (ROW, North America, Asia, and Europe) is
witnessed to grow USD 33.21 million, at a CAGR of 4% from 2019 to 2023”.
Free sample report contains market size and forecast, drivers,
challenges, trends, and more – Request for Sample @ https://www.technavio.com/talk-to-us?report=Global+Zika+Virus+Therapeutics+Market+2019-2023&type=sample&src=report
Global Zika Virus Therapeutics Market: Novel
approach for vaccine development
Various novel approaches are being developed to treat the chronic health
conditions occurring due to the Zika virus. Vendors in the market are
developing vaccines with modified RNA activity. These vaccines consist
of a lipid capsule encapsulating nanoparticle which is administered
through the intramuscular route. They also contain a modified messenger
RNA (mRNA), which is non-self-amplifying and optimizes the intracellular
stability, translation, and proprietary nucleoside alteration to prevent
the stimulation of innate immune response. Another vaccine developed
contains modified nucleoside 1-methylpseudouridine, which increases the
translation of mRNA. These newly developed vaccines are targeted at
producing a high concentration of antibodies against Zika virus
infection. Thus, the development of RNA vaccines against Zika virus is
likely to pave the way for other researchers to facilitate further R&D
in this area.
“Various government and non-government bodies are taking various
initiatives to develop vaccines against the Zika virus. Also, private
organizations are developing purified, inactivated, and whole virus
vaccines against the Zika virus infection. These initiatives and efforts
are further likely to contribute to the market’s growth during the
forecast period,” says a senior research analyst at Technavio.
Speak to Research Expert @ https://www.technavio.com/talk-to-us?report=Global+Zika+Virus+Therapeutics+Market+2019-2023&type=customization
Global Zika Virus Therapeutics Market:
Segmentation analysis
This market research report segments the global Zika virus therapeutics
market by product (acetaminophen, and other NSAIDs) and geographic
regions (ROW, North America, Asia, and Europe).
ROW led the market in 2018, followed by North America, Asia, and Europe
respectively. The region is expected to grow faster than the overall
market owing to increasing instances of this medical condition.
Global Zika Virus Therapeutics Market: Rising
prevalence of and burden of Zika virus
Zika virus infection gradually has witnessed several outbreaks reported
from various parts of the world. It is transmitted by infected mosquitos
and results in non-specific symptoms, including fever, myalgia, and
generalized fatigue. The market is witnessing a high incidence of the
Zika virus, which is expected to increase the patient pool leading to
increased consumption of Zika virus therapeutics. Thus, the growing
prevalence and burden of Zika virus infection and associated
comorbidities will foster market growth during the forecast period.
Few Major Players for the Zika Virus Therapeutics Market are:
- Aurobindo Pharma Ltd.
- Johnson & Johnson Services Inc.
- Perrigo Co. Plc
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
Browse Industries Reports @ Pharmaceuticals,
Biotechnology & Life Sciences
About Technavio
Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at [email protected].
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com